1
|
Abstract
Therapeutic drug monitoring is widely used in the anticonvulsant treatment of persons with epilepsy. Most monitoring uses serum, but many anticonvulsant drugs can as easily be monitored using saliva, including phenobarbital, phenytoin, carbamazepine, lamotrigine, oxcarbazepine, topiramate, levetiracetam, and gabapentin. For highly protein-bound medications such as phenobarbital, phenytoin, and carbamazepine, saliva has the advantage of providing an approximation of the serum free level, the free level presumably being the active moiety. Salivary therapeutic drug monitoring offers a number of advantages over serum therapeutic drug monitoring, including lack of pain, lower cost, and wide potential acceptability by patients and physicians. It has the potential to open new approaches to treatment with strategic at-home monitoring at the time a seizure or adverse event occurs and to allow the collection of cohort-based, pharmacokinetic, and pharmcodynamic data for populations of persons of varying ages and with different medical conditions who require anticonvulsant medications.
Collapse
Affiliation(s)
- Robert J. Baumann
- Department of Neurology, Kentucky Clinic, College of Medicine, University of Kentucky, Lexington, Kentucky, baumann @uky.edu
| |
Collapse
|
2
|
Hoagland D, Zhao Y, Lee RE. Advances in Drug Discovery and Development for Pediatric Tuberculosis. Mini Rev Med Chem 2016; 16:481-97. [PMID: 26202201 PMCID: PMC4964275 DOI: 10.2174/1389557515666150722101723] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/15/2015] [Revised: 06/11/2015] [Accepted: 07/12/2015] [Indexed: 01/28/2023]
Abstract
Pediatric tuberculosis is an underappreciated global epidemic estimated to afflict around half a million children worldwide. This problem has historically been overlooked, due in part to their low social status and the difficulty in diagnosis of tuberculosis in children. Children are more susceptible to tuberculosis infection and disease progression, including rapid dissemination into extrapulmonary infection sites. Treatment of pediatric tuberculosis infections has been traditionally built around agents used to treat the adult disease, but the disease pathology, drug pharmacokinetics and the safety window in children differs from the adult disease. This produces additional concerns for drug discovery and development of new agents. This review examines: (i) the safety concerns for current front and second line agents used to treat complex drug resistant infections and how this knowledge can be used to identify, prioritize and dose agents that may be better tolerated in pediatric populations; and (ii) the chemistry and suitability of new drugs in the clinical development pipeline for tuberculosis for the treatment of pediatric infections indicating several new agents may offer significant improvements for the treatment of multi-drug resistant tuberculosis in children.
Collapse
Affiliation(s)
| | | | - Richard E Lee
- Department of Chemical Biology and Therapeutics, St Jude Children's Research Hospital, MS#1000, Memphis, TN 38105, USA.
| |
Collapse
|
3
|
Kim SJ, Kim MY, Choi YM, Song MK. Effects of topiramate on language functions in newly diagnosed pediatric epileptic patients. Pediatr Neurol 2014; 51:324-9. [PMID: 24993246 DOI: 10.1016/j.pediatrneurol.2014.05.033] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 03/14/2014] [Revised: 05/30/2014] [Accepted: 05/31/2014] [Indexed: 10/25/2022]
Abstract
BACKGROUND The aim of this study was to characterize the effects of topiramate on language functions in newly diagnosed pediatric epileptic patients. METHODS Thirty-eight newly diagnosed epileptic patients were assessed using standard language tests. Data were collected before and after beginning topiramate during which time a monotherapy treatment regimen was maintained. Language tests included the Test of Language Problem Solving Abilities, a Korean version of the Peabody Picture Vocabulary Test. We used language tests in the Korean version because all the patients were spoken Korean exclusively in their families. RESULTS All the language parameters of Test of Language Problem Solving Abilities worsened after initiation of topiramate (determine cause, 13.2 ± 4.8 to 11.2 ± 4.3; problem solving, 14.8 ± 6.0 to 12.8 ± 5.0; predicting, 9.8 ± 3.6 to 8.8 ± 4.6). Patients given topiramate exhibited a shortened mean length of utterance in words during response (determine cause, 4.8 ± 0.9 to 4.3 ± 0.7; making inference, 4.5 ± 0.8 to 4.1 ± 1.1; predicting, 5.2 ± 1.0 to 4.7 ± 0.6; P < 0.05), provided ambiguous answers during the testing, exhibited difficulty in selecting appropriate words, took more time to provide answers, and used incorrect grammar. However, there were no statistically significant changes in the receptive language of patients after taking topiramate (95.4 ± 20.4 to 100.8 ± 19.1). CONCLUSIONS Our data suggest that topiramate may have negative effects on problem-solving abilities in children. We recommend performing language tests should be considered in children being treated with topiramate.
Collapse
Affiliation(s)
- Sun Jun Kim
- Department of Pediatrics, Chonbuk National University Medical School, Jeonju, Jeonbuk, Korea.
| | - Moon Yeon Kim
- Department of Pediatrics, Chonbuk National University Medical School, Jeonju, Jeonbuk, Korea
| | - Yoon Mi Choi
- Department of Pediatrics, Chonbuk National University Medical School, Jeonju, Jeonbuk, Korea
| | - Mi Kyoung Song
- Department of Pediatrics, Chonbuk National University Medical School, Jeonju, Jeonbuk, Korea
| |
Collapse
|
4
|
Linezolid- and Vancomycin-Resistant Enterococcus Faecium Peritonitis and Bacteremia Successfully Treated With Daptomycin in an Immunocompromised Pediatric Patient With Hepatic and Renal Failure. INFECTIOUS DISEASES IN CLINICAL PRACTICE 2012. [DOI: 10.1097/ipc.0b013e3182294bc5] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/17/2022]
|
5
|
Gopaul S, Farrell K, Abbott F. Effects of age and polytherapy, risk factors of valproic acid (VPA) hepatotoxicity, on the excretion of thiol conjugates of (E)-2,4-diene VPA in people with epilepsy taking VPA. Epilepsia 2003; 44:322-8. [PMID: 12614387 DOI: 10.1046/j.1528-1157.2003.07202.x] [Citation(s) in RCA: 63] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]
Abstract
PURPOSE Valproic acid (VPA) is an antiepileptic drug (AED) used for generalized and absence seizures. It has a rare but potentially fatal hepatotoxicity side effect, and many researchers believe that reactive metabolites of VPA could be involved. We demonstrated here that the thiol conjugates of (E)-2,4-diene VPA were significantly elevated in a high-risk group of patients. METHODS Thirty-four patients with seizures were divided into three groups. Group A (n = 14) were being treated with VPA; group B (n = 12) received VPA as well as other AEDs that do not induce P450-VPA metabolism; and group C (n = 8) received VPA and AEDs that induce P450-VPA metabolism. The NAC conjugates of (E)-2,4-diene VPA (NAC I and NAC II) were identified in the urine of patients by gas chromatography/mass spectrography NICI analysis. RESULTS VPA monotherapy (group A) or VPA polytherapy with non-P450-enzyme-inducing drugs (group B), showed that patients younger than 7.5 years excreted significantly higher concentrations of the two conjugates compared with older patients (older than 7.5 years) in the same groups (p < 0.05). Patients receiving VPA polytherapy with P450-enzyme-inducing drugs were all older than 7. 5 years (group C). They excreted significantly higher concentrations of NAC I and NAC II compared with patients in groups A and B who were older than 7.5 years (p < 0.05). CONCLUSIONS There were no significant differences in the excretion of NAC I and NAC II between patients in group C and those who were 7.5 years or younger in groups A and B. High doses of VPA also were a significant factor associated with elevated NAC I and NAC II among young patients and in polytherapy patients.
Collapse
Affiliation(s)
- Sashi Gopaul
- Faculties of Pharmaceutical Sciences and Medicine, University of British Columbia, Vancouver, British Columbia, Canada
| | | | | |
Collapse
|
6
|
Ziegler RG, Erba G, Holden L, Dennison H. The coordinated psychosocial and neurologic care of children with seizures and their families. Epilepsia 2000; 41:732-43. [PMID: 10840407 DOI: 10.1111/j.1528-1157.2000.tb00236.x] [Citation(s) in RCA: 16] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Abstract
SUMMARY As the medical and surgical management of epilepsy continues to advance, issues associated with the quality of life of patients and their families can be addressed. Whenever associated with other handicaps, such as learning disabilities, attentional or behavioral disorders, and problems in psychological adjustment, dual-diagnosis issues must be identified. To provide comprehensive care for children with epilepsy, a team approach to psychosocial assessment and treatment must be provided and coordinated with neurologic care. When the age-related needs in the life stage of the individual and family are identified, the best possible adaptation of the patient and his or her family can be supported.
Collapse
Affiliation(s)
- R G Ziegler
- Department of Psychiatry, Harvard Medical School, Division of Child and Adolescent Psychiatry, Community Relations, The Cambridge Health Alliance, Cambridge, Massachusetts, USA
| | | | | | | |
Collapse
|
7
|
Abstract
Progress in the diagnosis and management of seizure disorders and the availability of effective anticonvulsive medications has enabled increasing numbers of epileptic women of child-bearing age to raise families. Breast feeding, which these women may wish to choose, provides health, nutritional, immunological, developmental, social, economic and environmental benefits. The traditional anticonvulsants, such as phenytoin, carbamazepine and valproic acid (valproate sodium), are generally considered safe for use during breast feeding; however, observation for adverse effects is recommended. The use of phenobarbital while breast feeding is controversial because of its slow elimination by the nursing infant. The newer anticonvulsants, such as clobazam, felbamate, gabapentin, lamotrigine, oxcarbazepine, tiagabine, topiramate, and vigabatrin, are used mainly as adjunctive therapy. Data on the use of these drugs in pregnancy and lactation, and regarding long term effects on cognition and behaviour, are sparse. Weighing the benefits of breast feeding against the potential risk to the nursing infant, breast feeding is considered to be safe when the mother is taking carbamazepine, valproic acid or phenytoin. Infant monitoring for potential adverse effects is advisable when the mother is taking phenobarbital, clobazam, gabapentin, lamotrigine, oxcarbazepine or vigabatrin. Monitoring of infant serum drug concentrations is advisable but not compulsory. The use of felbamate, tiagabine and topiramate during breast feeding should await further study.
Collapse
Affiliation(s)
- B Bar-Oz
- The Department of Neonatology, Hadassah Medical Center, Jerusalem, Israel
| | | | | | | |
Collapse
|
8
|
Khurana DS, Riviello J, Helmers S, Holmes G, Anderson J, Mikati MA. Efficacy of gabapentin therapy in children with refractory partial seizures. J Pediatr 1996; 128:829-33. [PMID: 8648543 DOI: 10.1016/s0022-3476(96)70336-0] [Citation(s) in RCA: 77] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 02/01/2023]
Abstract
Thirty-two children with refractory partial epilepsy received open-label gabapentin as an additional medication to their antiepileptic drug regimen. Gabapentin was given in a dose ranging from 10 to 50 mg/kg per day (mean dose, 26.7 mg/kg daily). All patients had partial seizures with or without secondary generalization. Compared with baseline, 11 patients (34.4%) had a greater than 50% decrease in seizure frequency, and 4 (12.5%) had a 25% to 50% decrease in seizure frequency. Of the seven children who received the medication for 6 months or longer, two were seizure free and four were almost seizure free (having one seizure every few months). Mean gabapentin concentration was 4.8 micrograms/ml, and mean apparent clearance was 372 ml/kg per hour. The major reported side effects were behavioral. These consisted of hyperactivity, irritability, and agitation that occurred in patients with baseline mental retardation with attention deficit. We conclude that gabapentin can be a useful adjunctive medication in the treatment of refractory partial epilepsy in children.
Collapse
Affiliation(s)
- D S Khurana
- Department of Neurology, Children's Hospital, Harvard Medical School, Boston, Massachusetts, USA
| | | | | | | | | | | |
Collapse
|
9
|
Carmant L, Holmes GL, Sawyer S, Rifai N, Anderson J, Mikati MA. Efficacy of felbamate in therapy for partial epilepsy in children. J Pediatr 1994; 125:481-6. [PMID: 8071763 DOI: 10.1016/s0022-3476(05)83302-5] [Citation(s) in RCA: 40] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/28/2023]
Abstract
Thirty children (2 to 17 years of age) with refractory partial seizures received open-label felbamate as an add-on medication to their background antiepileptic drugs. The dose was increased up to a maximum of 45 mg/kg. Compared with baseline seizure activity, there was a 53% decrease in seizure frequency during felbamate therapy; 50% of the patients had more than a 50% decrease in seizure frequency. Patients older than 10 years of age were more likely to have a favorable response. Age correlated positively with felbamate concentrations and negatively with apparent felbamate clearance. Transient weight loss occurred in 57% of the patients; the weight loss was maximal after 12 weeks of initiation of felbamate, and subsided after the twentieth week of treatment. Anorexia and insomnia were reported in 20% and 16% of the patients, respectively. Adverse effects were generally tolerable; felbamate therapy was discontinued because of side effects in only one patient, because of a rash. We conclude that felbamate can be a useful and well-tolerated medication in the treatment of refractory partial epilepsy in children. However, increased apparent clearance of this drug in younger children should be considered in treatment of this age group.
Collapse
Affiliation(s)
- L Carmant
- Department of Neurology, Children's Hospital, Boston, MA 02115
| | | | | | | | | | | |
Collapse
|
10
|
Altrup U, Reith H, Speckmann EJ. Effects of valproate in a model nervous system (buccal ganglia of Helix pomatia): II. Epileptogenic actions. Epilepsia 1992; 33:753-9. [PMID: 1628594 DOI: 10.1111/j.1528-1157.1992.tb02357.x] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/27/2022]
Abstract
High concentrations of valproate (VPA; greater than 20 mM) depolarized identified neuronal individuals in the buccal ganglia of Helix pomatia and transiently induced paroxysmal depolarization shifts (PDS). Threshold concentration of VPA for the induction of PDS was decreased (a) by increased seizure susceptibility, (b) by increased concentrations of derivatives of VPA, and (c) by increased H+ concentrations. Intrasomatic injection of VPA did not induce PDS. The epileptogenic action of VPA is believed to be exerted from the extracellular side of the cell membrane.
Collapse
Affiliation(s)
- U Altrup
- Institut für Experimentelle Epilepsieforschung, Münster, Germany
| | | | | |
Collapse
|
11
|
Affiliation(s)
- N V O'Donohoe
- Department of Paediatrics, Trinity College, National Children's Hospital, Dublin, Republic of Ireland
| |
Collapse
|
12
|
Abstract
The emergency management of seizures often involves the use of diazepam as a first-line medication. Intravenous access is difficult in pediatric patients who are having seizures, and for this reason alternate routes of administration have been sought. This paper reviews the recent literature concerning the efficacy of rectal administration of intravenous diazepam solution for the purpose of emergency management of seizures in children. Although intravenous diazepam is the preferred route for the child with active seizure activity, undiluted diazepam intravenous solution administered per rectum is an excellent alternative. The technique of administration is reviewed.
Collapse
Affiliation(s)
- R S Seigler
- Childrens Hospital, Greenville, South Carolina
| |
Collapse
|
13
|
Abstract
A great number of anticonvulsants are available for treating these different types of epilepsy. Therapeutic drug monitoring has been favored as the method for controlling drug concentrations in the plasma and preventing untoward effects. When these anticonvulsants are prescribed to treat epilepsy in children, careful monitoring is most important because drug metabolism varies depending on maturation and development of body functions. Molecular approaches are also important to elucidate the effectiveness of the drugs for treatment of different seizure disorders and should contribute to a better understanding of body functions.
Collapse
Affiliation(s)
- I Matsuda
- Kumamoto University Medical School, Japan
| | | | | |
Collapse
|
14
|
Abstract
Antiepileptic drugs are effective even when metabolic, infectious, or structural lesions are present. Therefore, the underlying cause should be sought, and not just the seizure treated. After this is done, the drug therapy can be directed to controlling the seizure.
Collapse
Affiliation(s)
- W E Dodson
- Edward Mallinckrodt Department of Pediatrics, Washington University School of Medicine, St. Louis, Missouri
| |
Collapse
|
15
|
Abstract
About 75% of patients with epilepsy have seizures during childhood, often requiring antiepileptic therapy. Children possess all the drug-specific pharmacokinetic features of adults (e.g., nonlinearity of phenytoin elimination and autoinduction of carbamazepine metabolism), plus other factors (e.g., age, intercurrent illness, comedication) that influence dosage. Kinetic differences are maximal in newborns and infants, with limited drug elimination in premature and full-term babies, soon followed by accelerated elimination during infancy and childhood, before lower adult elimination rates develop during late childhood or early adolescence. Most children with epilepsy require two- to fourfold larger doses relative to bodyweight than adults, to achieve comparable drug levels and therapeutic effects. Although rapid growth may require increased dosage, the need is limited as relative clearance declines with age. Children of any age, but particularly premature and newborn babies, show greater individual variability in drug handling and therefore in dose requirements than adults. Clinical response and antiepileptic drug concentrations should both be monitored carefully in children.
Collapse
Affiliation(s)
- W E Dodson
- Washington University School of Medicine, St. Louis, Missouri
| |
Collapse
|